Cancer News and Research

Latest Cancer News and Research

Catch by Gene enters agreement with C&S for HPV test kit

Catch by Gene has entered into an agreement to supply its reagent solutions to C&S Company Ltd commencing immediately in the initial amount of $300,000.

13 Sep 2010

Current economic crisis threatens to affect cancer incidence: Report

Although overall mortality from cancer is decreasing in the European Union, its incidence increased by almost 20%, from 2.1 million new cases in 2002 to 2.5 million in 2008, says a special issue of the European Journal of Cancer on cancer prevention, published today.

13 Sep 2010

Measuring PSA levels effective in detecting prostate cancer: Study

A new multinational study suggests that regular blood testing to measure levels of prostate specific antigen (PSA) is more effective at detecting prostate cancer in men with a genetic predisposition to the disease.

13 Sep 2010

Enlyton publishes cancer imaging study results of colorectal cancer

Enlyton, Ltd., announced the publication of a cancer imaging study in which Enlyton's antigen-directed, cancer-specific targeting agent demonstrated superior performance over the industry standard, 18F-FDG, in Positron Emission Tomography (PET) imaging of colorectal cancer.

13 Sep 2010

PCRI to host educational event on prostate cancer therapy

Dean Ornish MD, recognized for establishing the impact of diet on prostate cancer (and heart disease), along with over a dozen internationally recognized prostate cancer experts will meet with over 800 prostate cancer survivors and their significant others at the Los Angeles Marriott near LAX on September 11th and 12th to discuss the latest thinking on prostate cancer treatment.

13 Sep 2010

Researchers elucidate Qua1 spatial structure region of Sam68 protein

Using NMR spectroscopy, Professor Michael Sattler and his team elucidated the spatial structure of the Qua1 region of Sam68, which is responsible for the dimerization of the protein. In collaboration with the research group of Professor Ruth Brack-Werner of the Institute of Virology, the authors showed that this region is essential for the biological function of Sam68.

13 Sep 2010

AABB to honor blood-collection professionals worldwide

Blood collection professionals are the connection between blood donors and the life-saving blood therapies people rely on every day. Blood-collection professionals will be recognized in communities worldwide September 12-18, 2010, as part of the 6th Annual Blood Collectors Week, sponsored jointly by Fenwal Inc. and AABB (formerly known as the American Association of Blood Banks).

13 Sep 2010

Genmab announces Phase II ofatumumab study results in RRMS patients

Genmab A/S announced today encouraging results from an ofatumumab Phase II safety and pharmacokinetics study in patients with relapsing-remitting multiple sclerosis (RRMS).

13 Sep 2010

Advaxis publishes research article on Her2 antigen for Listeria vaccine

Scientists at Advaxis, Inc.,the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, recently had their research using ADXS31-164, a live Listeria vaccine that targets Her2, published in a leading peer reviewed journal (Shahabi, et al 2010 Cancer Gene Therapy epublished ahead of print).

13 Sep 2010

Sun tanning still in demand for Victorian teenagers: Survey

According to the latest survey Victorian teenagers, despite skin cancer warnings, are still keen on getting a sun tan. The online survey by SunSmart showed that young Victorians are significantly more sun-safe than they were when the Slip! Slop! Slap! campaign first started 30 years ago.

12 Sep 2010

Pennsylvania Bio issues new report on Pennsylvania's bioscience companies' efforts for cancer research

Pennsylvania Bio today issued a new report on cancer that details the research happening through Pennsylvania companies to develop new products to diagnose and treat cancer.

12 Sep 2010

Johns Hopkins added as second clinical trial site in Tengion Neo-Urinary Conduit Phase I clinical trial

Tengion, Inc., a leader in regenerative medicine, announced today it has added The Johns Hopkins Hospital in Baltimore, Maryland as a second clinical trial site for its Phase I clinical trial of the Company's lead product candidate, the Tengion Neo-Urinary Conduit™, in bladder cancer patients requiring bladder removal.

10 Sep 2010

Doctor works to measure outcomes of provider care

Forbes profiles "the most powerful doctor you never heard of," a Yale cardiologist who does "outcomes research" in which he measures "how well doctors are doing in the real world, outside of controlled trials--what they are doing right, what they are doing wrong and what they are forgetting to do entirely."

10 Sep 2010

'Behind the counter' shop displays of cigarettes encourage smoking among youth

Young people believe 'behind the counter' shop displays of cigarettes encourage smoking and are considered "cool, fun and attractive" according to new research published in Health Promotion Practice.

10 Sep 2010

Good Start Genetics to develop pre-pregnancy genetic test with completed $18M Series A financing

Good Start Genetics, Inc., today announced the completion of an $18 million Series A financing. The proceeds of this financing will be used to complete the development and launch of the Company's pre-pregnancy genetic test, which utilizes advanced DNA sequencing technology to screen for a panel of genetic disorders including those recommended by the American Congress of Obstetricians and Gynecologists (ACOG) and the American College of Medical Genetics (ACMG).

10 Sep 2010

Varian to highlight new TrueBeam medical linear accelerator at ESTRO 2010

Varian Medical Systems is spotlighting its new TrueBeam™ medical linear accelerator for fast, powerful and efficient cancer treatments at the European Society for Therapeutic Radiology and Oncology exhibition in Barcelona next week. A fully-featured TrueBeam system will be the centerpiece of Varian's booth at the annual ESTRO meeting (Booth No. 320).

10 Sep 2010

Bioniche reduces net loss per share from $0.15 in fiscal 2009 to $0.02 in fiscal 2010

Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, today announced financial results for its 2010 fiscal year ended June 30, 2010.

10 Sep 2010

Ortho Biotech unblinded abiraterone acetate Phase 3 study for prostate cancer patients

Ortho Biotech Oncology Research & Development, a unit of Cougar Biotechnology, Inc., today announced that it has unblinded the Phase 3 study of abiraterone acetate plus prednisone for the treatment of patients with metastatic advanced prostate cancer (also referred to as castration-resistant prostate cancer) whose disease has progressed following treatment with one or two chemotherapy regimens at least one of which contained docetaxel.

10 Sep 2010

Structure of key protein for cellular signal transduction elucidated

Scientists of the Institute of Structural Biology of Helmholtz Zentrum München and the Technische Universität München have succeeded in elucidating the structure of an important region of the Sam68 protein. Sam68 is a key protein for cellular signal transduction. The Journal of Biological Chemistry has selected the report of these research findings as one of two "papers of the week" for its September 10, 2010 issue and has chosen the structural model as cover image.

10 Sep 2010

Nucletron to present innovative cancer treatment during ESTRO29

Nucletron, a leading provider of state of the art radiotherapy solutions for cancer treatment, today announced a large number of exciting innovations for precise cancer treatment that will be in the spotlight during ESTRO29 in Barcelona. The company will be showcasing the latest developments in cancer treatment solutions for both brachytherapy and external beam.

10 Sep 2010